File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.ejogrb.2006.07.023
- Scopus: eid_2-s2.0-33947501992
- PMID: 16920249
- WOS: WOS:000246159400013
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: A randomized comparison of side effects and patient convenience between Cyclogest® suppositories and Endometrin® tablets used for luteal phase support in IVF treatment
Title | A randomized comparison of side effects and patient convenience between Cyclogest® suppositories and Endometrin® tablets used for luteal phase support in IVF treatment |
---|---|
Authors | |
Keywords | Luteal phase support Patient convenience Side effects Vaginal progesterone |
Issue Date | 2007 |
Publisher | Elsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/ejogrb |
Citation | European Journal Of Obstetrics Gynecology And Reproductive Biology, 2007, v. 131 n. 2, p. 182-188 How to Cite? |
Abstract | Objective: This study compared side effects and patient convenience of vaginal progesterone suppositories (Cyclogest®) and vaginal progesterone tablets (Endometrin®) used for luteal phase support in in vitro fertilization/embryo transfer (IVF/ET) cycles using pituitary downregulation. Study design: One hundred and thirty-two infertile patients were randomized on the day of ET by a computer-generated randomization list in sealed envelopes to receive either Cyclogest® 400 mg or Endometrin® 100 mg twice daily for 14 days. On days 6 and 16 after ET, they rated side effects and patient convenience into four grades: none, mild, moderate and severe by completing a questionnaire. Results: No significant differences in perineal irritation were found on days 6 and 16 after ET between the two groups, although there was a trend of fewer patients with perineal irritation in the Endometrin® group. Significantly more patients in the Endometrin® group had difficulty of administration on day 6 after ET. There were no differences in the hormonal profile on day 6 after ET and IVF outcomes between the two groups. Conclusion: There was no difference in perineal irritation after the use of Cyclogest® suppositories or Endometrin® tablets for luteal phase support although more patients found administration of Endometrin® tablets difficult. © 2006 Elsevier Ireland Ltd. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/173320 |
ISSN | 2023 Impact Factor: 2.1 2023 SCImago Journal Rankings: 0.780 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ng, EHY | en_US |
dc.contributor.author | Chan, CCW | en_US |
dc.contributor.author | Tang, OS | en_US |
dc.contributor.author | Ho, PC | en_US |
dc.date.accessioned | 2012-10-30T06:29:17Z | - |
dc.date.available | 2012-10-30T06:29:17Z | - |
dc.date.issued | 2007 | en_US |
dc.identifier.citation | European Journal Of Obstetrics Gynecology And Reproductive Biology, 2007, v. 131 n. 2, p. 182-188 | en_US |
dc.identifier.issn | 0301-2115 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/173320 | - |
dc.description.abstract | Objective: This study compared side effects and patient convenience of vaginal progesterone suppositories (Cyclogest®) and vaginal progesterone tablets (Endometrin®) used for luteal phase support in in vitro fertilization/embryo transfer (IVF/ET) cycles using pituitary downregulation. Study design: One hundred and thirty-two infertile patients were randomized on the day of ET by a computer-generated randomization list in sealed envelopes to receive either Cyclogest® 400 mg or Endometrin® 100 mg twice daily for 14 days. On days 6 and 16 after ET, they rated side effects and patient convenience into four grades: none, mild, moderate and severe by completing a questionnaire. Results: No significant differences in perineal irritation were found on days 6 and 16 after ET between the two groups, although there was a trend of fewer patients with perineal irritation in the Endometrin® group. Significantly more patients in the Endometrin® group had difficulty of administration on day 6 after ET. There were no differences in the hormonal profile on day 6 after ET and IVF outcomes between the two groups. Conclusion: There was no difference in perineal irritation after the use of Cyclogest® suppositories or Endometrin® tablets for luteal phase support although more patients found administration of Endometrin® tablets difficult. © 2006 Elsevier Ireland Ltd. All rights reserved. | en_US |
dc.language | eng | en_US |
dc.publisher | Elsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/ejogrb | en_US |
dc.relation.ispartof | European Journal of Obstetrics Gynecology and Reproductive Biology | en_US |
dc.rights | European Journal of Obstetrics & Gynecology and Reproductive Biology. Copyright © Elsevier Ireland Ltd. | - |
dc.subject | Luteal phase support | - |
dc.subject | Patient convenience | - |
dc.subject | Side effects | - |
dc.subject | Vaginal progesterone | - |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Dose-Response Relationship, Drug | en_US |
dc.subject.mesh | Estradiol - Blood | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Fertilization In Vitro - Methods | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Infertility, Female - Drug Therapy - Physiopathology | en_US |
dc.subject.mesh | Luteal Phase - Drug Effects | en_US |
dc.subject.mesh | Pituitary Gland - Drug Effects - Physiopathology | en_US |
dc.subject.mesh | Progesterone - Administration & Dosage - Pharmacology - Therapeutic Use | en_US |
dc.subject.mesh | Suppositories - Adverse Effects | en_US |
dc.subject.mesh | Time Factors | en_US |
dc.subject.mesh | Vaginal Creams, Foams, And Jellies - Adverse Effects | en_US |
dc.title | A randomized comparison of side effects and patient convenience between Cyclogest® suppositories and Endometrin® tablets used for luteal phase support in IVF treatment | en_US |
dc.type | Article | en_US |
dc.identifier.email | Ng, EHY:nghye@hkucc.hku.hk | en_US |
dc.identifier.email | Ho, PC:pcho@hku.hk | en_US |
dc.identifier.authority | Ng, EHY=rp00426 | en_US |
dc.identifier.authority | Ho, PC=rp00325 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/j.ejogrb.2006.07.023 | en_US |
dc.identifier.pmid | 16920249 | - |
dc.identifier.scopus | eid_2-s2.0-33947501992 | en_US |
dc.identifier.hkuros | 133344 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-33947501992&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 131 | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.spage | 182 | en_US |
dc.identifier.epage | 188 | en_US |
dc.identifier.isi | WOS:000246159400013 | - |
dc.publisher.place | Ireland | en_US |
dc.identifier.scopusauthorid | Ng, EHY=35238184300 | en_US |
dc.identifier.scopusauthorid | Chan, CCW=26643394500 | en_US |
dc.identifier.scopusauthorid | Tang, OS=36881248500 | en_US |
dc.identifier.scopusauthorid | Ho, PC=7402211440 | en_US |
dc.identifier.issnl | 0301-2115 | - |